FDA Approval Sought for Lurbinectedin in Small Cell Lung Cancer
A new drug application has been submitted to the FDA seeking an accelerated approval for lurbinectedin for use as a second-line treatment for patients with small cell lung cancer.
Related Articles
Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma
Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.
Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy
Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.
FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors
The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
Innovative Research Continues to Propel Individualized GIST Treatments
Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.
Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years
A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously…
Zanubrutinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis
An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
Mendoza, Weiss Receive $2.6 Million Grant to Study Biomechanics of Lung Tumors
Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth…
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.
Biomarker Consortium – Onclive
To bring key stakeholders (HCPs, pharmaceutical and biotech companies, associations, and advocacy groups) together for the common purpose of providing accurate and relevant information to…
Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL
Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.